DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a medical stage biotechnology firm creating allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome enhancing platform, immediately introduced it’s going to take part within the Guggenheim Healthcare Talks 2021 Genomic Medicines & Uncommon Illness Day on April 1, 2021.
Particulars for the presentation are under:
Guggenheim Healthcare Talks | 2021 Genomic Medicines & Uncommon Illness Day
Panel: On the Cusp of Genomic Medication and Cell Remedy for Dyslipidemia and T1DM
Presenter: Derek Jantz, Ph.D., Chief Scientific Officer
Date: Thursday, April 1, 2021
Time: 8:00-8:50 AM ET
A stay webcast of the presentation can be accessible on the Firm’s web site, www.precisionbiosciences.com, within the Buyers & Media part below Occasions and Shows. An archived replay of the webcasts can be out there for about 30 days following the presentation.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a medical stage biotechnology firm devoted to enhancing life (DTIL) with its wholly proprietary ARCUS® genome enhancing platform. ARCUS is a extremely particular and versatile genome enhancing platform that was designed with therapeutic security, supply, and management in thoughts. Utilizing ARCUS, the Firm’s pipeline consists of a number of “off-the-shelf” CAR T immunotherapy medical candidates and a number of other in vivo gene correction remedy candidates to remedy genetic and infectious illnesses the place no satisfactory therapies exist. For extra details about Precision BioSciences, please go to www.precisionbiosciences.com.
Interim Chief Monetary Officer
Senior Director, Company Communications